CTOs on the Move

Pernix Therapeutics Holdings, Inc.

www.pernixtx.com

 
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pernixtx.com
  • 10 N Park Pl Ste 201
    Morristown, NJ USA 07960
  • Phone: 800.793.2145

Executives

Name Title Contact Details

Similar Companies

Sha Pharmaceuticals

Sha Pharmaceuticals is a Pelham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

St. Joseph Children's Home

We providing a continuum of care through our three programs: Foster Care and Adoption Program, Residential Treatment Program, and Child Development Center.

Genactis

Genactis is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PAR Pharmaceuticals

PAR Pharmaceuticals is a Woodcliff Lake, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.